Alterations in the fibrinolytic system components during acute myocardial infarction

E Ioannidou-Papayannaki1, N Lefkos, G Boudonas

  • 1Haematology Laboratory of 2nd Dept. of Internal Medicine, Aristotelian University of Thessaloniki, Hippokration Hospital, Greece.

Acta Cardiologica
|October 21, 2000
PubMed

Insights

This study investigated changes in tissue-plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), and D-dimer (DD) in acute myocardial infarction patients post-thrombolytic therapy. Elevated t-PA, PAI-1, and DD levels correlated with infarct size, aiding treatment assessment.

Area of Science:

  • Cardiology
  • Biochemistry
  • Thrombolysis

Background:

  • Acute myocardial infarction (AMI) involves blood clot formation.
  • Thrombolytic therapy aims to dissolve these clots.
  • Biomarkers like t-PA, PAI-1, and D-dimer reflect coagulation and fibrinolysis states.

Purpose of the Study:

  • To assess changes in plasma t-PA, PAI-1, and D-dimer levels in AMI patients after thrombolytic therapy.
  • To compare these changes between rt-PA and acetyl-streptokinase treatments.
  • To explore correlations between these markers and infarct size estimated by peak serum CPK levels.

Main Methods:

  • Enzyme immunoassay (Stago) was used to measure plasma levels of t-PA, PAI-1, and D-dimer.
  • 57 AMI patients and 25 healthy controls were included.
  • Plasma samples were collected at baseline, 4 hours, and 24 hours post-therapy.

Main Results:

  • AMI patients exhibited higher baseline t-PA, PAI-1, and D-dimer levels compared to controls.
  • Thrombolytic therapy led to significant increases in t-PA, PAI-1, and D-dimer at 4 hours.
  • While t-PA and D-dimer remained elevated at 24 hours, PAI-1 returned to baseline levels. No significant differences were observed between rt-PA and acetyl-streptokinase treatments.
  • t-PA and PAI-1 levels positively correlated with infarct size.

Conclusions:

  • Thrombolytic therapy significantly alters coagulation and fibrinolysis markers in AMI patients.
  • These marker changes are related to infarct size, potentially aiding in treatment monitoring.
  • Both rt-PA and acetyl-streptokinase demonstrated similar effects on these biomarkers.

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...